Quantitative Measurement of Progesterone Receptor Immunohistochemical Expression to Predict Lymph Node Metastasis in Endometrial Cancer
Open Access
- 23 March 2022
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 790
Abstract
Background: Previous studies have shown that loss of progesterone receptor (PR) in endometrial cancer (EC) is associated with poor outcomes. Evaluating lymph node metastasis (LNM) is essential, especially before surgical staging. The aim of this study was to investigate the role of PR expression and other clinicopathological parameters in LNM and to develop a prediction model. Methods: We retrospectively evaluated endometrioid-type EC patients treated with staging surgery between January 2015 and March 2020. We analyzed PR status using immunohistochemical staining, and the expression was quantified using the H-score. We identified optimal cut-off values of H-score and CA125 for predicting LNM using receiver operating characteristic curves, and used stepwise multivariate logistic regression analysis to identify independent predictors. A nomogram for predicting LNM was constructed and validated using bootstrap resampling. Results: Of the 310 patients evaluated, the optimal cut-off values of PR H-score and CA125 were 162.5 (AUC 0.670, p = 0.001) and 40 U/mL (AUC 0.739, p < 0.001), respectively. Multivariate analysis showed that CA125 ≥ 40 U/mL (OR: 8.03; 95% CI: 3.44–18.77), PR H-score < 162.5 (OR: 5.22; 95% CI: 1.87–14.60), and tumor grade 2/3 (OR: 3.25; 95% CI: 1.33–7.91) were independent predictors. These three variables were incorporated into a nomogram, which showed effective discrimination with a concordance index of 0.829. Calibration curves for the probability of LNM showed optimal agreement between the probability as predicted by the nomogram and the actual probability. Our model gave a negative predictive value and a negative likelihood ratio of 98.4% and 0.14, respectively. Conclusions: PR H-score along with tumor grade and CA125 are helpful to predict LNM. In addition, our nomogram can aid in decision making with regard to lymphadenectomy in endometrioid-type EC.Keywords
This publication has 32 references indexed in Scilit:
- Interobserver Agreement Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast CarcinomaAmerican Journal of Clinical Pathology, 2012
- Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancerGynecologic Oncology, 2012
- Preoperative Identification of a Low-Risk Group for Lymph Node Metastasis in Endometrial Cancer: A Korean Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2012
- Revised FIGO staging for carcinoma of the endometriumInternational Journal of Gynecology & Obstetrics, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinomaThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group studyGynecologic Oncology, 2004
- Can a Preoperative CA 125 Level Be a Criterion for Full Pelvic Lymphadenectomy in Surgical Staging of Endometrial Cancer?Gynecologic Oncology, 2002
- Surgical Staging of Endometrial Cancer: Evolution, Evaluation, and Responsible Challenge—A Personal PerspectiveGynecologic Oncology, 1997